JP2007505901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505901A5 JP2007505901A5 JP2006526855A JP2006526855A JP2007505901A5 JP 2007505901 A5 JP2007505901 A5 JP 2007505901A5 JP 2006526855 A JP2006526855 A JP 2006526855A JP 2006526855 A JP2006526855 A JP 2006526855A JP 2007505901 A5 JP2007505901 A5 JP 2007505901A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- compound
- formula
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 17
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 206010014561 Emphysema Diseases 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 19
- -1 R 21 Chemical compound 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- VMNXLLDFGVEBLE-UHFFFAOYSA-N (4-methylsulfonylphenyl)methanamine Chemical compound CS(=O)(=O)C1=CC=C(CN)C=C1 VMNXLLDFGVEBLE-UHFFFAOYSA-N 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- NJQRAAHKQQPUIT-UHFFFAOYSA-N 1,2-dihydropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CNC1 NJQRAAHKQQPUIT-UHFFFAOYSA-N 0.000 claims 1
- PCMTWAVEXLEEHR-UHFFFAOYSA-N 1-(3-chlorophenyl)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-6-methyl-2-oxopyridine-3-carboxylic acid Chemical compound CC1=NOC(C)=C1C1=C(C)N(C=2C=C(Cl)C=CC=2)C(=O)C(C(O)=O)=C1 PCMTWAVEXLEEHR-UHFFFAOYSA-N 0.000 claims 1
- HNXAHLRULHAYNU-UHFFFAOYSA-N 5-(3,5-dimethyl-1,2-oxazol-4-yl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxylic acid Chemical compound CC1=NOC(C)=C1C1=C(C)N(C=2C=C(C=CC=2)C(F)(F)F)C(=O)C(C(O)=O)=C1 HNXAHLRULHAYNU-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302486A SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Novel compounds |
| PCT/SE2004/001335 WO2005026123A1 (en) | 2003-09-18 | 2004-09-15 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007505901A JP2007505901A (ja) | 2007-03-15 |
| JP2007505901A5 true JP2007505901A5 (OSRAM) | 2010-01-28 |
| JP4515455B2 JP4515455B2 (ja) | 2010-07-28 |
Family
ID=29212488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526855A Expired - Lifetime JP4515455B2 (ja) | 2003-09-18 | 2004-09-15 | 好中球エラスターゼ阻害剤としての２−ピリドン誘導体およびそれらの使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8063073B2 (OSRAM) |
| EP (1) | EP1663973B3 (OSRAM) |
| JP (1) | JP4515455B2 (OSRAM) |
| KR (1) | KR101141464B1 (OSRAM) |
| CN (1) | CN1882542B (OSRAM) |
| AR (1) | AR045761A1 (OSRAM) |
| AU (1) | AU2004272484C1 (OSRAM) |
| BR (1) | BRPI0414548B8 (OSRAM) |
| CA (1) | CA2538405C (OSRAM) |
| CO (1) | CO5670358A2 (OSRAM) |
| ES (1) | ES2448465T7 (OSRAM) |
| IL (1) | IL173990A (OSRAM) |
| IS (1) | IS8381A (OSRAM) |
| MX (1) | MXPA06002724A (OSRAM) |
| MY (1) | MY143400A (OSRAM) |
| NO (1) | NO20061660L (OSRAM) |
| NZ (1) | NZ545963A (OSRAM) |
| RU (1) | RU2353616C2 (OSRAM) |
| SA (1) | SA04250299B1 (OSRAM) |
| SE (1) | SE0302486D0 (OSRAM) |
| TW (1) | TWI354665B (OSRAM) |
| UY (1) | UY28514A1 (OSRAM) |
| WO (1) | WO2005026123A1 (OSRAM) |
| ZA (1) | ZA200602261B (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| SE0302487D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| TW200700392A (en) * | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| PH12012502411A1 (en) | 2005-05-10 | 2019-07-17 | Intermune Inc | Method of modulating stress-activated protein kinase system |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| EP1924553A1 (en) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| GB0605469D0 (en) * | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
| TW200808771A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| TW200808763A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| EP2066662B1 (en) * | 2006-09-21 | 2012-12-05 | Kyorin Pharmaceutical Co., Ltd. | Serine hydrolase inhibitors |
| GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| CA2681311A1 (en) * | 2007-04-13 | 2008-10-23 | Novartis Ag | Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonisis |
| HUE036704T2 (hu) | 2007-05-22 | 2018-07-30 | Wyeth Llc | Továbbfejlesztett eljárás hidrazidok elõállítására |
| WO2009058076A1 (en) * | 2007-11-02 | 2009-05-07 | Astrazeneca Ab | 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| EA017297B1 (ru) | 2007-11-06 | 2012-11-30 | Астразенека Аб | Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы |
| US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| US8334236B2 (en) | 2009-02-03 | 2012-12-18 | Kumiai Chemical Industry Co., Ltd. | Ring-fused 2-pyridone derivatives and herbicides |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| US8367836B2 (en) * | 2009-04-27 | 2013-02-05 | Elan Pharmaceuticals, Inc. | Pyridinone antagonists of alpha-4 integrins |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| AU2010302420B2 (en) | 2009-10-02 | 2013-07-04 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| JP2013512954A (ja) * | 2009-12-08 | 2013-04-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換インダゾール及びアザインダゾール化合物の生成に有効な中間体の合成方法 |
| WO2011073662A1 (en) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| EP2562174A1 (de) * | 2011-08-24 | 2013-02-27 | Bayer Cropscience AG | Herbizid wirksame 6-Oxo-1,6-dihydropyrimidin-5-carboxamide und 2-Oxo-1,2-dihydropyridin-3-carboxamide |
| TWI485146B (zh) | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
| US9102624B2 (en) | 2012-08-23 | 2015-08-11 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US20140057920A1 (en) | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US20140057926A1 (en) | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US9221807B2 (en) * | 2014-02-21 | 2015-12-29 | Boehringer Ingelheim International Gmbh | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity |
| AU2015232543B2 (en) * | 2014-03-17 | 2019-09-26 | Daiichi Sankyo Company,Limited | 1,3-benzodioxole derivative |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| WO2016168696A1 (en) | 2015-04-15 | 2016-10-20 | Ohio State Innovation Foundation | Methods to improve induction of iga antibodies by vaccines |
| CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
| AU2020349353A1 (en) | 2019-09-17 | 2022-04-14 | Duke University | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
| ES2962498T3 (es) | 2020-04-16 | 2024-03-19 | Mereo Biopharma 4 Ltd | Métodos que implican el inhibidor de elastasa de neutrófilos alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina |
| KR20240090272A (ko) | 2021-10-20 | 2024-06-21 | 메레오 바이오파마 4 리미티드 | 섬유화 치료에 사용하기 위한 호중구 엘라스테이스 억제제 |
| TW202440630A (zh) * | 2023-01-09 | 2024-10-16 | 財團法人國家衛生研究院 | 治療釋網凋亡介導之疾病的方法 |
| WO2025056602A1 (en) | 2023-09-11 | 2025-03-20 | Elastin Biosciences Ltd. | Pharmaceutical compositions and use thereof in treatment of conditions and diseases related to elastin deficiency and/or aging |
| WO2025078838A1 (en) | 2023-10-11 | 2025-04-17 | Mereo Biopharma 4 Limited | Alvelestat and alpha- 1 antitrypsin for treating respiratory disorders |
| WO2025133628A1 (en) | 2023-12-21 | 2025-06-26 | Mereo Biopharma 4 Limited | Use of alvelestat in specific patients |
| GB202319953D0 (en) | 2023-12-22 | 2024-02-07 | Mereo Biopharma 4 Ltd | Tablet formulations involving alvelestat |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1067079A (en) * | 1976-07-22 | 1979-11-27 | Yamanouchi Pharmaceutical Co. | Nitrogen-containing heterobicyclic compounds |
| DE2706977A1 (de) * | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
| EP0008864A1 (en) | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| JPH02152966A (ja) | 1988-12-05 | 1990-06-12 | Otsuka Pharmaceut Co Ltd | ４−ヒドロキシカルボスチリル誘導体 |
| US5521179A (en) * | 1991-04-18 | 1996-05-28 | Zeneca Limited | Heterocyclic amides |
| US5441960A (en) * | 1992-04-16 | 1995-08-15 | Zeneca Limited | 1-pyrimidinylacetamide human leukocyte elastate inhibitors |
| BR9713863A (pt) | 1996-12-05 | 2000-03-14 | Amgen Inc | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase |
| JPH1171351A (ja) * | 1997-08-29 | 1999-03-16 | Ss Pharmaceut Co Ltd | 置換キノロン誘導体及びこれを含有する医薬 |
| CY2010012I2 (el) * | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| KR100850728B1 (ko) * | 2000-06-12 | 2008-08-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 1,2-디하이드로피리딘 화합물, 그의 제조 방법 및 그의 용도 |
| CN100575345C (zh) * | 2000-12-28 | 2009-12-30 | 盐野义制药株式会社 | 对2型大麻素受体具有结合活性的吡啶酮衍生物 |
| EP1417967A4 (en) * | 2001-08-14 | 2007-03-28 | Toyama Chemical Co Ltd | NEW VIRUS PROTECTION INHIBITION, VIRCIDIDIC PROCEDURE AND NEW PYRADIN NUCLEOTIDE / PYRADIN NUCLEOSIDE ANALOGON |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| GB2383326A (en) * | 2001-12-20 | 2003-06-25 | Bayer Ag | Antiinflammatory dihydropyridines |
| MXPA03000145A (es) * | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| AU2003211442A1 (en) * | 2002-02-19 | 2003-09-09 | Shionogi And Co., Ltd. | Antipruritics |
| TWI280128B (en) * | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| US7230017B2 (en) | 2002-08-27 | 2007-06-12 | Bayer Healthcare Ag | Dihydropyridinone derivatives |
| GB2392910A (en) | 2002-09-10 | 2004-03-17 | Bayer Ag | 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302323D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302324D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302487D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| JP5134248B2 (ja) | 2004-02-19 | 2013-01-30 | バイエル・ファルマ・アクチェンゲゼルシャフト | ジヒドロピリジノン誘導体 |
| ES2394177T3 (es) | 2004-02-26 | 2013-01-23 | Bayer Intellectual Property Gmbh | 1,4-diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| TW200700392A (en) | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| GB0512940D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Compounds and their use |
| GB0605469D0 (en) | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
| MX2008013996A (es) | 2006-05-04 | 2009-01-14 | Argenta Discovery Ltd | Tetrahidropirrolopirimidindionas y su uso como inhibidores de elastasa de neutrofilo humano. |
| TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| TW200808763A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| WO2008003158A1 (en) | 2006-07-07 | 2008-01-10 | Detlef Gerhard Meier | Pipe lifter and line up tool |
| WO2008030158A1 (en) | 2006-09-04 | 2008-03-13 | Astrazeneca Ab | Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors |
| WO2008104752A1 (en) | 2007-02-26 | 2008-09-04 | Astrazeneca Ab | Dihydropyridones as elastase inhibitors |
| WO2009058076A1 (en) | 2007-11-02 | 2009-05-07 | Astrazeneca Ab | 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| EA017297B1 (ru) * | 2007-11-06 | 2012-11-30 | Астразенека Аб | Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы |
| CN101481352A (zh) * | 2008-01-10 | 2009-07-15 | 上海恒瑞医药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
-
2003
- 2003-09-18 SE SE0302486A patent/SE0302486D0/xx unknown
-
2004
- 2004-09-13 TW TW093127684A patent/TWI354665B/zh not_active IP Right Cessation
- 2004-09-15 EP EP04775438.7A patent/EP1663973B3/en not_active Expired - Lifetime
- 2004-09-15 ES ES04775438T patent/ES2448465T7/es active Active
- 2004-09-15 US US10/572,706 patent/US8063073B2/en active Active
- 2004-09-15 RU RU2006112428/04A patent/RU2353616C2/ru active
- 2004-09-15 KR KR1020067005456A patent/KR101141464B1/ko not_active Expired - Lifetime
- 2004-09-15 UY UY28514A patent/UY28514A1/es not_active Application Discontinuation
- 2004-09-15 MX MXPA06002724A patent/MXPA06002724A/es active IP Right Grant
- 2004-09-15 CN CN2004800338474A patent/CN1882542B/zh not_active Expired - Lifetime
- 2004-09-15 WO PCT/SE2004/001335 patent/WO2005026123A1/en not_active Ceased
- 2004-09-15 NZ NZ545963A patent/NZ545963A/xx not_active IP Right Cessation
- 2004-09-15 CA CA2538405A patent/CA2538405C/en not_active Expired - Lifetime
- 2004-09-15 AU AU2004272484A patent/AU2004272484C1/en not_active Expired
- 2004-09-15 BR BRPI0414548A patent/BRPI0414548B8/pt active IP Right Grant
- 2004-09-15 JP JP2006526855A patent/JP4515455B2/ja not_active Expired - Lifetime
- 2004-09-16 MY MYPI20043743A patent/MY143400A/en unknown
- 2004-09-17 AR ARP040103355A patent/AR045761A1/es not_active Application Discontinuation
- 2004-09-18 SA SA04250299A patent/SA04250299B1/ar unknown
-
2006
- 2006-02-27 IL IL173990A patent/IL173990A/en not_active IP Right Cessation
- 2006-03-15 CO CO06026216A patent/CO5670358A2/es active IP Right Grant
- 2006-03-17 ZA ZA200602261A patent/ZA200602261B/en unknown
- 2006-03-28 IS IS8381A patent/IS8381A/is unknown
- 2006-04-11 NO NO20061660A patent/NO20061660L/no not_active Application Discontinuation
-
2011
- 2011-10-14 US US13/273,860 patent/US8501784B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505901A5 (OSRAM) | ||
| ES2316575T3 (es) | Derivado de fenilpiridincarbonilpiperazina. | |
| FI116219B (fi) | Aromaattiset aminoeetterit kipua lievittävinä aineina | |
| ES2203649T3 (es) | Sulfonamidas. | |
| JP4479152B2 (ja) | 複素環誘導体及び医薬 | |
| RU2361860C2 (ru) | Новые замещенные 3-сера-индолы | |
| JP5494482B2 (ja) | トリアゾール誘導体またはその塩 | |
| KR100802332B1 (ko) | 신규한 3-치환된 요소 유도체 및 그의 의학적 용도 | |
| JP2006519258A5 (OSRAM) | ||
| BRPI0414548B1 (pt) | derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso | |
| TWI314555B (en) | Heterocyclic derivatives | |
| RU2008140910A (ru) | Новые пиперидины в качестве модуляторов хемокинов (ccr) | |
| CN100427469C (zh) | 作为嗜中性白细胞弹性蛋白酶抑制剂的喹啉衍生物及它们的用途 | |
| CN102239164A (zh) | 2h-色烯化合物及其衍生物 | |
| CN1826120A (zh) | 用于发炎与免疫相关用途的化合物 | |
| MXPA05004818A (es) | Derivados de 2-piridona como inhibidores de la neutrofilo elastasa. | |
| RU2008143457A (ru) | Производные-2-пиразинона для лечения заболевания или состояния, при которых полезно ингибирование активности нейтрофильной эластазы | |
| JP2010505809A5 (OSRAM) | ||
| JP2011502982A5 (OSRAM) | ||
| RU2007134106A (ru) | Новые соединения ii, являющиеся производными 2-пиридина, в качестве ингибиторов | |
| JP2008516968A5 (OSRAM) | ||
| JP2008533137A5 (OSRAM) | ||
| JP2006507247A5 (OSRAM) | ||
| JPWO2008146774A1 (ja) | テトラヒドロイソキノリン−１−オン誘導体またはその塩 | |
| JP2008513405A5 (OSRAM) |